MARKET

IMAB

IMAB

I-MAB
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.16
-3.10
-7.70%
After Hours: 37.17 +0.01 +0.03% 19:29 11/24 EST
OPEN
39.88
PREV CLOSE
40.26
HIGH
39.95
LOW
37.13
VOLUME
148.31K
TURNOVER
--
52 WEEK HIGH
47.46
52 WEEK LOW
9.30
MARKET CAP
2.62B
P/E (TTM)
-11.9428
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
I-Mab's C5aR antibody TJ210/MOR210 shows strong scientific rationale as potential treatment for cancers
I-Mab (IMAB) announces new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer ((SITC)) Annual Meeting.TJ210/MOR210
Seekingalpha · 11/11 13:19
I-Mab Announces Preclinical Data on Differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced new preclinical data from in vivo and in vitro studies of its C5aR antibody project, TJ210/MOR210, at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting. The data will be shared in an oral presentation entitled "TJ210 (MOR210), A Differentiated Anti-C5aR Antibody for Anti-Cancer Therapy", on November 12, 2020 at 11:30 am EST (Abstract 607).
PR Newswire · 11/11 13:00
I-Mab To Present Preclinical Data Of TJ210 At 2020 Society For Immunotherapy Of Cancer (SITC) Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 27, 2020 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and
Benzinga · 10/27 12:18
Week In Review: Zai Lab Completes Second Listing With $761 Million HK IPO
Zai Lab raised $761 million in a Hong Kong IPO and rose 8.5% in its first trading session to a market cap of $6.8 billion.Fosun Pharma of Shanghai closed its $182 million in-licensing of China rights to balixafortide with Switzerland's Polyphor AG.Shanghai's I-Mab reported China approval to conduct a Phase III trial of eftansomatropin as a once-weekly treatment for growth hormone deficiency in pediatric patients.
Seekingalpha · 10/04 20:37
Mid-Afternoon Market Update: Dow Jumps 350 Points; Iterum Therapeutics Shares Spike Higher
Toward the end of trading Wednesday, the Dow traded up 1.28% to 27,804 while the NASDAQ rose 0.83% to 11177.49. The S&P also rose, gaining 0.92% to 3,366.11.
Benzinga · 09/30 19:55
I-Mab on go with China study of eftansomatropin in dwarfism
Chinese regulators have signed off on an open-label Phase 3 clinical trial evaluating I-Mab's (IMAB) eftansomatropin for the weekly treatment of growth hormone deficiency (dwarfism) in pediatric patients.The primary objective
Seekingalpha · 09/30 12:39
I-Mab Receives China CDE Approval To Initiate Phase 3 Clinical Trial Of Eftansomatropin In Pediatric Patients With Growth Hormone Deficiency
SHANGHAI and GAITHERSBURG, Md., Sept. 30, 2020 /PRNewswire/ --I-Mab (the "Company") (NASDAQ:IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and
Benzinga · 09/30 12:03
Week In Review: Zai Lab To Raise Up To $845 Million In Hong Kong IPO
Zai Lab of Shanghai is conducting a Hong Kong IPO that is expected to raise up to $845 million, offering 12.3% of the company's expanded number of shares.Tianjin JuveStar Biotech, a Fosun Pharma affiliate, acquired Greater China rights to an aesthetic product from Israel's Raziel Therapeutics in a $74 million agreement.Shanghai's I-Mab and MorphoSys AG of Munich announced they have permission to start US trials of an anti-C5aR1 antibody in patients with advanced solid tumors.
Seekingalpha · 09/21 19:34
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMAB. Analyze the recent business situations of I-MAB through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMAB stock price target is 54.33 with a high estimate of 58.09 and a low estimate of 51.03.
EPS
Institutional Holdings
Institutions: 50
Institutional Holdings: 9.50M
% Owned: 13.47%
Shares Outstanding: 70.50M
TypeInstitutionsShares
Increased
8
743.68K
New
30
4.43M
Decreased
5
332.16K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About IMAB
I-Mab is a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of I-Mab ADR stock information, including NASDAQ:IMAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMAB stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMAB stock methods without spending real money on the virtual paper trading platform.